Another UCLA study adds fuel to the ongoing debate regarding hormone replacement therapy (HRT). Concerns exist regarding whether estrogen and progestin are better or worse than just giving women estrogen alone. In women who still have not had a hysterectomy, progestin counteracts the increased risk of uterine cancer when estrogen is given alone; however, it increases the risk of breast cancer. The new study by researchers at UCLA’s Jonsson Comprehensive Cancer Center has found that women taking the combination estrogen and progestin menopausal hormone therapy who experienced new onset breast tenderness had a 33% greater subsequent risk of developing breast cancer than women who did not experience breast tenderness. In contrast, among women taking estrogen alone, those who experienced new-onset breast tenderness did not have a higher subsequent risk of breast cancer. “This study showed that developing new breast tenderness after the start of hormone therapy was associated with increased breast cancer risk only in women on the combination estrogen plus progestin therapy, not estrogen therapy alone.” said study first author Dr. Carolyn Crandall, a professor of general internal medicine and a scientist with UCLA’s Jonsson Comprehensive Cancer Center
The study appears in the November 17 early online edition of the peer-reviewed journal Breast Cancer Research and Treatment. A previous study by Dr. Crandall, published last month, found that the new onset of breast tenderness was much more pronounced after initiation of estrogen and progestin therapy than in women getting estrogen therapy alone. The association between new onset breast tenderness and changes in breast density also was more pronounced in the women getting the combination hormone therapy. “The consistent theme we’ve run across throughout these studies is that estrogen and progestin compared to estrogen alone have a more marked effect on breast tissue,” Dr. Crandall said. “One theory is that there may be more growth of breast tissue, making the breasts more dense, when women take the combination therapy.” She added that multiple population studies have shown that higher breast density is associated with a higher risk of breast cancer. In women with extremely dense breasts, the cancer risk can be four to six times higher than for women whose breasts are not dense.
Women taking estrogen did experience breast tenderness; however, it was less than women on the combination therapy, and it clearly did not signal an increased risk of breast cancer. Dr. Crandall cautioned that women taking hormone therapy in general are only at a slight risk for developing breast cancer overall. A previous study estimated that, out of 10,000 women who take combination estrogen plus progestin hormone therapy for one year, eight additional women developed breast cancer than would have normally have been expected to get the disease.
Dr. Crandall said it’s too early to call for an increase in the frequency of clinical breast exams and mammograms in women on hormone therapy based on these studies. However, a woman on hormone therapy who experiences new onset breast tenderness should be vigilant about getting her regular clinical breast exams and mammograms. One finding in this study was expected, that estrogen and progestin has a greater impact on the breast and that women on the combination therapy had more breast tenderness than women on estrogen alone. What was surprising, Dr. Crandall said, was that women taking estrogen alone did have breast tenderness, but that did not correlate to increased risk of breast cancer.
For this prospective study, the researchers analyzed data from more than 27,337 women enrolled in the Women’s Health Initiative (WHI). Of the 27,337 women, 16,608 were on the combination therapy, while 10,739 were taking estrogen alone. Launched in 1991, the WHI consisted of a set of clinical trials and an observational study involving161,808 healthy, postmenopausal women.